HIV Treatment Snapshot: Dolutegravir
Published Monday, June 19, 2017
Dolutegravir (DTG) belongs to a newer class of antiretroviral medicines known as integrase inhibitors. It is used for the treatment of HIV in combination with other antiretrovirals in adults, adolescents, and older children. The World Health Organization (WHO) has recommended its use as an alternate first-line medicine, which could substantially change the landscape for ART scale-up and implementation. Because it is a highly durable drug and less susceptible to the emergence of resistance, access to DTG in countries that need it is an emerging issue in the global HIV/AIDS response. This snapshot provides a summary of key regulatory information, clinical research, and current pricing of DTG.
Download the full PDF by clicking here or the image below.